Shares closed at $171.16 on Friday as the S&P 500 rose 0.84% to 7,398.93 and the Dow Jones Industrial Average added 0.02% to 49,609.16.
Danaher ended 29.51% below its 52-week high of $242.80 reached on 22 January, while trading volume of 4.6 million topped its 50-day average of 4.4 million.
Among peers, Thermo Fisher fell 1.99%, Abbott dropped 3.09% and Medtronic lost 2.32%, leaving Danaher with a mixed relative performance in a broadly positive market session.
Why is Danaher's stock falling despite a positive earnings forecast and major AI-focused acquisitions?
With China rising as a biotech powerhouse, can Danaher's acquisition spree secure its global dominance?
Can Danaher's multi-billion dollar bet on AI diagnostics overcome the healthcare industry's crippling cost and labor crises?